SNSE
vs
S&P 500
SNSE
S&P 500
Over the past 12 months, SNSE has significantly outperformed S&P 500, delivering a return of +255% compared to the S&P 500's +15% growth.
Stocks Performance
SNSE vs S&P 500
Performance Gap
SNSE vs S&P 500
Performance By Year
SNSE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sensei Biotherapeutics Inc
Glance View
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 56 full-time employees. The company went IPO on 2021-02-04. The firm is engaged in the discovery and development of therapies with focus on treatments for cancer. Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. The firm is engineering its ImmunoPhage product candidates to directly target antigen presenting cells (APCs) and modulate the tumor microenvironment (TME) through the targeted use of nanobodies which enhances therapeutic activity. SNS-301 is an ImmunoPhage product candidate that the Company is developing as a treatment for locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN). The company also develops ImmunoPhage candidate, SNS-401, for the treatment of Merkel cell carcinoma (MCC). The firm is also engaged in developing a monoclonal antibody (mAb) therapy.
